← Leaderboards
Constance M John
Mandalmed, Inc.
$2,994,888
Attributed
$4,718,240
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,718,240 · 10
By mechanism
R43$2,492,301 · 9
R44$2,225,939 · 1
Top collaborators
- Matthew Lawrence Springer5 shared
- Maurizio Chiriva-Internati1 shared
- Khalid Mounzih1 shared
- Paul Jacob Turek1 shared
Most similar at Mandalmed, Inc.
Same institution · by research overlap
- Maurizio Chiriva-Internati$831,918
- Khalid Mounzih$153,436
Others in their field
Top investigators on “Toxicology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- David Heimbrook · Leidos Biomedical Research, Inc.$155,080,196
- Barney Sparrow · Battelle Memorial Institute$96,886,832
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Robert H Vonderheide · University Of Pennsylvania$78,967,264
- Reshan Fernando · Research Triangle Institute$70,521,464
Research focus
ToxicologyPharmaceutical PreparationsProteinsAnimalsInhibitor/AntagonistGalectin 3BaseLectinCessation Of LifeIn VitroImmuneResponsePreventAnimal ModelProductionGalactose Binding LectinOrganRattusDrug KineticsLeadMediatingIncidenceCellsIschemia
Grant awards (14)
Cell-based Gene Therapy for MPS IVA$306,872
R43 · FY2024 · AR
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction$1,061,083
R44 · FY2018 · AG · contact PI
Biologic Inhibitor of Galectin-3 for Liver Fibrosis$299,900
R43 · FY2018 · DK · contact PI
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction Supplement$131,530
R44 · FY2018 · AG · contact PI
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction$808,592
R44 · FY2017 · AG · contact PI
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction$224,734
R44 · FY2016 · AG · contact PI
Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction$299,958
R43 · FY2013 · HL · contact PI
Model of the Human Testis for Reproductive Toxicology$250,000
R43 · FY2011 · ES · contact PI
Preclinical Testing of Galectin-3C for Multiple Myeloma$363,936
R43 · FY2008 · CA · contact PI
Human Sertoli Cell Model for Study of Male Reproductive Function and Toxicity$255,200
R43 · FY2007 · HD · contact PI
Novel biomarkers for neuronal damage in multiple sclerosis$174,760
R43 · FY2006 · AI · contact PI
Novel Treatment for Breast Cancer: Truncated Galectin-3$255,495
R43 · FY2002 · CA
Novel Treatment for Breast Cancer: Truncated Galectin-3$236,893
R43 · FY2001 · CA
PLACENTAL CELLS FOR PROTECTION OF IMPLANTED B ISLETS$49,287
R43 · FY2000 · DK